Parkinson's disease psychosis (PDP) is one of the most debilitating non-motor complications of Parkinson's disease, affecting up to 50% of patients during disease progression. Visual hallucinations are the most common manifestation, typically occurring in the evening hours (Charles Bonnet syndrome) and often progressing to complex visual and auditory hallucinations, delusions, and paranoid ideation. The pathophysiology involves multiple neurotransmitter systems, with particular emphasis on serotonergic dysregulation and cortical visual processing disturbances. [1] [2]
Nelotanserin (ACD-004) is a selective 5-HT2A serotonin receptor inverse agonist developed by ACADIA Pharmaceuticals as a potential treatment for Parkinson's disease psychosis. Unlike pimavanserin (the only FDA-approved treatment for PDP), nelotanserin was designed with enhanced inverse agonist properties, potentially providing more complete inhibition of constitutive receptor activity. [3]
| Attribute | Value |
|---|---|
| Category | Treatment |
| Target Indication | Parkinson's Disease Psychosis |
| Mechanism | 5-HT2A serotonin receptor inverse agonist |
| Company | ACADIA Pharmaceuticals |
| Clinical Phase | Phase II completed |
| Route | Oral administration |
| Target | 5-HT2A receptor (HTR2A gene) |
The serotonin 2A receptor (5-HT2A) is a G-protein coupled receptor (GPCR) expressed abundantly in the prefrontal cortex, claustrum, and visual cortex regions. It plays a critical role in modulating cortical pyramidal neuron activity, perceptual processing, and the integration of sensory information. In Parkinson's disease, 5-HT2A receptor binding is significantly increased in the visual and prefrontal cortices, correlating with the presence and severity of visual hallucinations. [4] [5]
Unlike classical antagonists that merely block endogenous serotonin binding, inverse agonists actively suppress constitutive (ligand-independent) receptor activity. This distinction is clinically relevant because:
Parkinson's disease psychosis results from a complex interplay of dopaminergic, serotonergic, and cholinergic dysfunction:
Neuroimaging studies have identified specific regional changes associated with PDP:
| Factor | Description | Impact |
|---|---|---|
| Disease duration | Longer PD duration | Higher psychosis risk |
| Age | Older age at onset | Increased susceptibility |
| Cognitive impairment | MCI or early dementia | Strongest predictor |
| Dopaminergic therapy | Higher doses, longer use | Medication-induced psychosis |
| Visual impairment | Reduced visual acuity | Visual hallucinations |
| Sleep disorders | REM behavior disorder | Associated with psychosis |
A randomized, double-blind, placebo-controlled Phase II study evaluated nelotanserin in PD patients with visual hallucinations. The trial design included:
| Feature | Nelotanserin | Pimavanserin |
|---|---|---|
| Mechanism | Inverse agonist | Inverse agonist |
| Selectivity | 5-HT2A selective | 5-HT2A > 5-HT2C |
| Receptor affinity (Ki) | 0.5 nM | 2.0 nM |
| Formulation | Oral tablet | Oral tablet |
| Dosing | Once daily | Once daily |
| FDA approval | Not approved | Approved (2016) |
| Phase | Phase II complete | Phase III complete |
Ideal candidates for 5-HT2A inverse agonist therapy:
Contraindications:
| Treatment | Mechanism | Status | Key Limitation |
|---|---|---|---|
| Pimavanserin | 5-HT2A inverse agonist | FDA-approved | Cardiac arrhythmia risk |
| Nelotanserin | 5-HT2A inverse agonist | Phase II | Not yet approved |
| Quetiapine | D2 antagonist | Off-label | Sedation, metabolic |
| Clozapine | D2 antagonist | Off-label | Agranulocytosis risk |
| Rivastigmine | Cholinesterase inhibitor | Approved for PDD | GI side effects |
Fénelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors. Brain. 2003. ↩︎
Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease. Parkinsonism Relat Disord. 2007. ↩︎
Weiner C, Meltzer HY, Katona C. 5-HT2A inverse agonists for the treatment of Parkinson's disease psychosis. Nat Rev Drug Discov. 2020. ↩︎
Joutsa J, Rinne JO, Eskola O, Bergman J. 5-HT2A receptor binding and psychosis in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2018. ↩︎
Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 5-HT2A receptors and visual hallucinations in Parkinson's disease. Arch Gen Psychiatry. 2010. ↩︎
Huot P, Johnston TH, Darr T, et al. 5-HT2A receptor inverse agonists as novel antipsychotic agents for Parkinson's disease. J Pharmacol Exp Ther. 2018. ↩︎
Bhome R, Price G, Collins JD, et al. Neuroimaging correlates of psychosis in Parkinson's disease: A systematic review. J Parkinsons Dis. 2021. ↩︎
Tkač I, Coman EL, Melamed E, et al. Neuroimaging of 5-HT2A receptors in Parkinson's disease psychosis. Neuroimage Clin. 2020. ↩︎